216 related articles for article (PubMed ID: 28991707)
21. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
[TBL] [Abstract][Full Text] [Related]
22. Clinical spectrum and prognosis of pathologically confirmed atypical tumefactive demyelinating lesions.
Zhang Y; Zhang T; Zhang X; Yan X; Lei J; Liu R; Yang Y; Zhang C; Zhang J; Zhang Y; Yue W
Sci Rep; 2023 May; 13(1):7773. PubMed ID: 37179394
[TBL] [Abstract][Full Text] [Related]
23. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of pathological characteristics of acute and chronic cerebral tumefactive demyelinating lesions].
Sun C; Liu J; Gui Q; Lu D; Qi X
Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(45):3557-61. PubMed ID: 25622833
[TBL] [Abstract][Full Text] [Related]
25. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.
Vakrakou AG; Tzanetakos D; Evangelopoulos ME; Argyrakos T; Tzartos JS; Anagnostouli M; Andreadou E; Koutsis G; Velonakis G; Toulas P; Gialafos E; Dimitrakopoulos A; Psimenou E; Stefanis L; Kilidireas C
Ther Adv Neurol Disord; 2021; 14():17562864211006503. PubMed ID: 34046086
[TBL] [Abstract][Full Text] [Related]
26. Tumefactive demyelinating lesions: nine cases and a review of the literature.
Xia L; Lin S; Wang ZC; Li SW; Xu L; Wu J; Hao SY; Gao CC
Neurosurg Rev; 2009 Apr; 32(2):171-9; discussion 179. PubMed ID: 19172322
[TBL] [Abstract][Full Text] [Related]
27. Pediatric tumefactive demyelination: case series and review of the literature.
McAdam LC; Blaser SI; Banwell BL
Pediatr Neurol; 2002 Jan; 26(1):18-25. PubMed ID: 11814730
[TBL] [Abstract][Full Text] [Related]
28. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
[TBL] [Abstract][Full Text] [Related]
29. Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients.
Nagappa M; Taly AB; Sinha S; Bharath RD; Mahadevan A; Bindu PS; Saini JS; Prasad C; Shankar SK
Acta Neurol Scand; 2013 Jul; 128(1):39-47. PubMed ID: 23277913
[TBL] [Abstract][Full Text] [Related]
30. Tumefactive demyelinating lesions: a clinicopathological correlative study.
Neelima R; Krishnakumar K; Nair MD; Kesavadas C; Hingwala DR; Radhakrishnan VV; Nair SS
Indian J Pathol Microbiol; 2012; 55(4):496-500. PubMed ID: 23455787
[TBL] [Abstract][Full Text] [Related]
31. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim N; Kim HS; Choi CG; Lim YM
AJR Am J Roentgenol; 2015 Apr; 204(4):827-34. PubMed ID: 25794073
[TBL] [Abstract][Full Text] [Related]
32. Kidney Transplant Recipient With Tumefactive Demyelinating Lesions: A Case Report and Literature Review.
Mu L; Wang M; Cheng L; Liu P; Wang K
Transplant Proc; 2023 Oct; 55(8):1906-1909. PubMed ID: 37541863
[TBL] [Abstract][Full Text] [Related]
33. Tumefactive demyelination: an approach to diagnosis and management.
Hardy TA; Chataway J
J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1047-53. PubMed ID: 23334629
[TBL] [Abstract][Full Text] [Related]
34. [A case of pediatric multiple sclerosis presenting with a tumefactive demyelinating lesion].
Majima H; Ito T; Koyama N
Rinsho Shinkeigaku; 2017 Feb; 57(2):88-91. PubMed ID: 28132974
[TBL] [Abstract][Full Text] [Related]
35. Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome.
Ekmekci O; Eraslan C
Case Rep Neurol Med; 2018; 2018():8409247. PubMed ID: 30622825
[TBL] [Abstract][Full Text] [Related]
36. [Dynamic features of tumefactive demyelinating lesions in different clinical stages by contrast-enhanced magnetic resonance imaging].
Song DD; Qi XK; Liu JG; Zhao HL; Wang QJ; Diao DW; Wang QQ
Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(43):3513-3518. PubMed ID: 30481901
[No Abstract] [Full Text] [Related]
37. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.
Enzinger C; Strasser-Fuchs S; Ropele S; Kapeller P; Kleinert R; Fazekas F
Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384
[TBL] [Abstract][Full Text] [Related]
38. Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study.
Chew SH; Achmad Sankala HB; Chew E; Md Arif MHB; Mohd Zain NR; Hashim H; Koya Kutty SB; Chee YC; Mohd Saleh NB; Ong BH; Viswanathan S
Mult Scler Relat Disord; 2023 Nov; 79():104992. PubMed ID: 37717306
[TBL] [Abstract][Full Text] [Related]
39. Tumefactive Multiple Sclerosis Masquerading as High Grade Glioma.
Lin M; Reid P; Bakhsheshian J
World Neurosurg; 2018 Apr; 112():37-38. PubMed ID: 29331745
[TBL] [Abstract][Full Text] [Related]
40. Tumefactive demyelinating lesion: experience with two unusual patients.
Sinha MK; Garg RK; Bhatt ML; Chandra A
J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
